Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKinsey
Express Scripts
AstraZeneca
Mallinckrodt

Last Updated: August 19, 2022

OXTELLAR XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Oxtellar Xr patents expire, and what generic alternatives are available?

Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are ten patents protecting this drug and two Paragraph IV challenges.

This drug has fourteen patent family members in ten countries.

The generic ingredient in OXTELLAR XR is oxcarbazepine. There are twenty-one drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Oxtellar Xr

A generic version of OXTELLAR XR was approved as oxcarbazepine by GLENMARK PHARMS LTD on October 9th, 2007.

  Try it Free

Drug patent expirations by year for OXTELLAR XR
Drug Prices for OXTELLAR XR

See drug prices for OXTELLAR XR

Recent Clinical Trials for OXTELLAR XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Colorado, DenverPhase 4
Collaborative Care Initiative, LLCPhase 4
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen HospitalPhase 4

See all OXTELLAR XR clinical trials

Pharmacology for OXTELLAR XR
Anatomical Therapeutic Chemical (ATC) Classes for OXTELLAR XR
Paragraph IV (Patent) Challenges for OXTELLAR XR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OXTELLAR XR Extended-release Tablets oxcarbazepine 150 mg and 300 mg 202810 1 2013-04-12
OXTELLAR XR Extended-release Tablets oxcarbazepine 600 mg 202810 1 2013-03-20

US Patents and Regulatory Information for OXTELLAR XR

OXTELLAR XR is protected by ten US patents.

Patents protecting OXTELLAR XR

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Modified-release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Method of treating seizures using modified release formulations of oxcarbazepine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF PARTIAL-ONSET SEIZURES

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Modified release preparations containing oxcarbazepine and derivatives thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for OXTELLAR XR

See the table below for patents covering OXTELLAR XR around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2359830 Préparations à libération contrôlée d'oxcarbazépine disposant d'un profil à libération sigmoïdale (Controlled released preparations of oxcarbazepine having sigmoidal release profile) See Plans and Pricing
Spain 2360423 See Plans and Pricing
Germany 602007012236 See Plans and Pricing
Australia 2007242984 Controlled released preparations of oxcarbazepine having sigmoidal release profile See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Johnson and Johnson
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.